|
Drug Design and Discovery (DDD) Section |
 |
|
 |

ABOUT THE DDD SECTION
Who We Are:
The DDD Section engages in all aspects of the design and discovery of molecular
pharmaceutical entities, and fosters interactions at the interface between drug
discovery and development. DDD provides leadership and a forum for interactions
among scientists from academia, industry, and research institutions. The section
invites and supports collaborative relationships with scientists in other disciplines
within AAPS and other scientific and professional organizations whose efforts are
directed toward the interface of drug design and discovery and drug development.
The DDD Section is truly unique among scientific organizations serving the needs
of medicinal and natural products chemists and scientists engaged in other emerging
technologies and disciplines involved in drug development, including druggability,
by providing a single organization for all members associated with pharmaceutical
drug discovery and development.
What We Do:
DDD encourages the discovery, dissemination, integration and application of knowledge
concerning the chemistry, biochemistry, and pharmacological actions of synthetic
and naturally occurring medicinal agents. Research activities leading to this knowledge
involve the study of the physicochemical properties related to the structure and
function of drugs, drug design and synthesis, and drug targeting at enzyme active
sites, receptors, transporters, lipid membranes and other sites at which the influence
of a drug as a bound ligand influences physiologic processes. These are accomplished
using high throughput technologies, computational methodologies and molecular modeling,
the use of microbial or mammalian enzyme systems for the prediction and production
of mammalian drug metabolites, isolation of biologically active natural products
from plant, animal, and microbial sources and their characterization through modern
spectroscopic methods, and the relation of chemical structure and subsequent modification
to the pharmacological activity of small molecules and macromolecules.
How We Do It:
DDD encourages joint membership with other sections of AAPS to foster greater understanding
of the primacy of discovery and design in all aspects of the pharmaceutical development
pipeline. The multidisciplinary nature of this section and of AAPS is conducive
to a productive interaction between all segments of the pharmaceutical sciences.
For this reason, the DDD Section is committed to joint symposia and other programs
with various AAPS Sections in an effort to provide an atmosphere for the professional
growth of its member scientists.
Drug Discovery Development Interface:
The Drug Design and Discovery Section is closely involved in the AAPS initiative
concerning ways to characterize and optimize the drug-like properties of structural
hits and leads, referred to as the Drug Discovery Development Interface (D3I). The
DDD Section will assist in the creation of a D3I Collaborative, which should include
representatives from basic, science-oriented sister organizations; and participate
in the generation of a Drug Discovery-Development Roadmap, which will guide scientific
programming and educational offerings.
Resources
ACS Division of Medicinal Chemistry
AAPS Section Connection
The "Section Connection" is intended to serve as a conduit for the exchange
of information between the AAPS Executive Council (EC) and Sections. This information
will be assembled by Staff and the Section Member-at-Large following each EC meeting
to provide a summary of pertinent actions that are relevant to Section leaders.
Likewise, the Member-at-Large will transmit important Sectional information to the
EC and use "Section Connection" as the recording mechanism of Section
interests shared with the EC.
|
|
 |
 |
 |
 |
|
Committee Descriptions
Chair Nurulain T. Zaveri, Ph.D. Astraea Therapeutics, LLC Saratoga, CA United States
| Chair-Elect Thomas E. Prisinzano, Ph.D. University of Kansas Department of Medicinal Chemistry Lawrence, KS
| Vice Chair Lee Jia, Ph.D. National Cancer Institute Rockville, MD UNITED STATES
| Secretary/Treasurer Susan L. Mercer, Ph.D. Lipscomb University College of Pharmacy Nashville, TN United States
| Past Chair Christopher R. McCurdy, Ph.D. University of Mississippi University, MS UNITED STATES
| Member at Large Gary A. Thompson, Ph.D. GA Thompson Consulting, LLC Cincinnati, OH United States
| Annual Meeting Screeners Committee Shridhar V. Andurkar, Ph.D. Midwestern University Downers Grove, IL United States
| National Biotechnology Conference Screeners Committee Cornelis J. Van der Schyf Northeastern Ohio Universities College of Pharmacy Rootstown, OH
| Annual Meeting Program Committee Thomas E. Prisinzano, Ph.D. University of Kansas Department of Medicinal Chemistry Lawrence, KS
| Awards Committee Alexandros Makriyannis, Ph.D. Northeastern UniversityCenter for Drug Discovery Boston, MA United States
| Content Advisory Cmte Robin M. Zavod, Ph.D. Midwestern University Downers Grove, IL UNITED STATES
| National Biotech Progrming Committee Chang-Guo Zhan, Ph.D. University of Kentucky Lexington, KY UNITED STATES
| Student/Postdoc Committee Cornelis J. Van der Schyf Northeastern Ohio Universities College of Pharmacy Rootstown, OH
| Fellows Committee Rao S. Rapaka, Ph.D. NIDA Gaithersburg, MD UNITED STATES
| Nominations Committee Nurulain T. Zaveri, Ph.D. Astraea Therapeutics, LLC Saratoga, CA United States
| Program Coordination Committee Christopher R. McCurdy, Ph.D. University of Mississippi University, MS UNITED STATES
| Webmasters Committee Edward B. Roche, Ph.D. Univ. of Nebraska Medical Center Omaha, NE United States
| Student Rep Swapnil J. Kulkarni University of Mississippi University, MS
| Member Strategic Oversight Committee Annette Bak, Ph.D. Merck & Co Rahway, NJ United States
| Staff Liaison Stacey Anne May AAPS Alexandria, VA United States
| Staff Liaison Maria Nadeau AAPS Arlington, VA United States
| CRO Focus Group Lee Jia, Ph.D. National Cancer Institute Rockville, MD UNITED STATES
| Computational Drug Design Focus Group Herschel J. R. Weintraub CADDinformatics, Inc. Sun City, AZ United States
| Natural Products Chemistry Focus Group David A. Colby, Pharm.D., Ph.D. Purdue University West Lafayette, IN United States
| Nutraceuticals Focus Group Jairaj Mehta JM Pharma, LLC Peoria, AZ UNITED STATES
| Pharmacogenomics (PGx) Focus Group Okezie I. Aruoma, MBA, Ph.D., D.Sc. Touro College of Pharmacy New York, NY
| Targeted Drug Delivery and Prodrug Focus Group Victor R Guarino Bristol-Myers Squibb Princeton, NJ UNITED STATES
|
JOIN THE DDD LISTSERVE
To join the DDD Section Listserve click here.
|
|